NuGene International, Inc. Sees 40.6% Reduction in Wrinkles and Fine Lines in Second Princeton Consumer Research Study

IRVINE, CA--(Marketwired - Jun 4, 2015) - NuGene International, Inc. ("NuGene") (OTCQB: NUGN), a developer, manufacturer and marketer of advanced skin and hair care lines utilizing adipose derived human stem cells and stem cell media, has announced the findings of a second study designed to evaluate the efficacy of NuGene's Universal Serum and Eye Serum compared to untreated skin. This follows the reported results for NuGene's Universal Cream® announced in May.

Princeton Consumer Research conducted a single-blinded, bi-lateral facial site study on 28 healthy male and female subjects over 35 years old with aged skin to evaluate the anti-aging efficacy of NuGene's Universal Serum and Eye Serum over an eight week period. 

The NuGene's active site showed a statistically significant improvement from baseline as early as 4 weeks of treatment in all objective and subjective assessments. The conclusion of the study revealed that Universal Serum and Eye Serum applied side had a 40.65% reduction of fine lines and wrinkles (expert visual assessment) and 20.39% improvement in the moisture level (corneometer) after eight weeks of treatment.

"This is another objective third party study on our products that supports our marketing claims," said Dr. M. Saeed Kharazmi, NuGene's Chairman, when announcing the findings. "As with our Universal Cream, the actively treated sites showed significant improvement over untreated sites. Using these products simultaneously should provide an even greater impact. We are happy and proud to share these results with the public."

Four measurements were used for this study. A Corneometer® was used to assess skin hydration. A profilometry analysis was performed to examine expression-induced lines (crow's feet.) Expert visual assessments were performed by the same qualified person throughout the test period. A Visia-CR Capture technology was used to capture images of all subjects' faces during the assessments. Finally, each subject was provided with a self-perception questionnaire for evaluating the product attributes and to get their opinions on the efficacy of the product.

No adverse reactions were reported during the study. The placebo sites on each subject's face showed no significant changes during the study. The active treated sites, on the other hand, showed statistically significant changes from baseline following both four and eight week assessments.

About NuGene International, Inc.
NuGene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media. The US Department of Health and Human Services calls regenerative medicine the "next evolution of medical treatments." The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report. NuGene's cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue. NuGene's exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations. The company has four patents pending covering 15 unique applications and inventions. NuGene's goal is to leverage its knowledge and expertise to develop age defying cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.

Forward-Looking Statements
This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by NuGene International may not proceed as contemplated, and by all other matters and assumptions specified in NuGene's filings with the Securities and Exchange Commission, especially those risks and other matters described under "Risk Factors" within NuGene's Form 10-Q filed with the Commission on May 15, 2015. These statements are made based upon current expectations that are subject to risk and uncertainty. NuGene does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information.